You are here: Industry Insights > UCB

News List

UCB to buy rare disease therapies developer Zogenix for $1.9bn Pharmaceutical-Technology
January 21, 2022
The company’s subsidiary will be merged into Zogenix and the remaining shares of Zogenix common stock will be cancelled.
UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis AmericanPharmaceuticalReview
December 13, 2021
UCB announced positive topline results from the Phase 3 MycarinG study1 evaluating rozanolixizumab, a subcutaneously (SC) infused monoclonal antibody targeting the neonatal Fc receptor (FcRn), versus placebo in adults with generalized myasthenia gravis...
UCB and Novartis to co-develop two drug candidates for Parkinson’s Disease Pharmaceutical-Technology
December 06, 2021
Belgian pharmaceutical firm UCB has signed an agreement with Novartis to develop disease-modifying treatments for Parkinson’s Disease (PD) patients.
Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms prnewswire
November 22, 2021
UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results from the Phase 3 BE OPTIMAL study assessing the efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor...
FDA misses approval target dates after plant inspections delayed by COVID travel restrictions CPhIonline
October 21, 2021
The US Food and Drug Administration has told UCB Pharma that it was unable to complete a review of the company’s Biologics License Application for its psoriasis treatment...
Interim trial data for UCB’s bimekizumab shows positive results pharmatimes
August 09, 2021
Interim data from a trial for UCB’s investigational IL-17A and IL-17F inhibitor bimekizumab in adults with moderate to severe plaque psoriasis have been presented during a presentation at the 2021 American Academy of Dermatology (AAD) summer meeting ...
UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis pharmatimes
August 03, 2021
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD), recommending UCB’s bimekizumab as an option for the treatment of adults with severe plaque psoriasis.
CHMP recommends approval of UCB’s Bimzelx for plaque psoriasis pharmatimes
June 29, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for UCB’s Bimzelx as a treatment for moderate-to-severe plaque psoriasis.
UCB and Microsoft expand drug development partnership pharmaceutical-technology
February 25, 2021
UCB and Microsoft have entered into a new multi-year, strategic collaboration.The collaboration will merge Microsoft’s computational services, Cloud and artificial intelligence (AI) with UCB’s drug discovery and development capabilities.
UCB’s bimekizumab data in plaque psoriasis published in The Lancet pharmatimes
February 05, 2021
Data from two Phase III studies of UCB’s investigational treatment bimekizumab in moderate-to-severe plaque psoriasis have been published in The Lancet.

Previous page 1 2 3 4 5 6 Next page